Increased R&D Interest to Drive the Global Market for Nanotechnology in Drug Delivery, According to a Soon to be Released Report by Global Industry Analysts, Inc.

Share Article

GIA announces the launch of a comprehensive primary research program studying the global market for “Nanotechnology in Drug Delivery”. The soon to be released report identifies strong R&D investments, technology breakthroughs, and increased competitive pressure on companies to develop novel delivery approaches for existing drug compounds, as key market driving forces.

Nanotechnology in Drug Delivery: A Global Multi-Client Research Initiative

Follow us on LinkedIn – GIA invites senior industry executives, domain experts, technologists and market strategists to participate in a comprehensive global research initiative studying the market for Nanotechnology in Drug Delivery. The study will examine key drivers and trends impacting the market such as technology developments in drug delivery nanosystems; expanding nanotechnology applications in nasal, oral and epidermal drug delivery routes; heavy R&D investments and development of novel nanocarriers; breakthrough developments in the concept of “Clever” drug targeting systems.

An important sector of the Nanomedicine industry, Nanotechnology in Drug Delivery is defined as the application of nanotechnology in drug delivery. Nano Drug Delivery techniques involve encapsulation of nano size particles of drugs in polymer matrices that have targeting ligands that bind to diseased cells for controlled release of drugs. Key benefits of nano drug delivery systems triggering R&D interests include targeted and accurate intracellular delivery of drugs and reduced immune system response and resulting side effects; sustained and controlled release of drugs for optimum clinical impact and patient outcome; and superior retention of bioactivity of drugs by protecting them from environmental degradation. Promising areas of nanodrug delivery systems which are expected to witness the maximum impact in terms of investor interest and market opportunities include injectable drugs, oral drugs, implantable drug delivery systems, external topical delivery, and transdermal delivery, among others.

The upcoming years are expected to witness nanodrug delivery systems expand to include drug compounds for cancer and infectious diseases. R&D efforts are already underway to develop ethylene glycol molecules based nanoparticles capable of transporting chemotherapy drugs directly to tumour cells. Another key breakthrough in the oncology field is the development of nanosponge drug delivery system capable of significantly reducing tumour growth as compared to conventional injectable drugs. Cardiology also represents a promising area with studies underway to develop nanoparticles to deliver clot busting drugs. In this regard, iron oxide based nanoparticles are being researched for their ability to deliver drugs directly to stents implanted within the arteries.

A key factor fuelling R&D investments in nanodrug delivery systems is the growing pressure on pharmaceutical companies to develop breakthrough novel next generation drugs against a backdrop of intense competition from generics as most second generation drugs continue to lose patents. Also the aging world population is pushing up unmet medical needs among the elderly creating an urgent need for novel and effective therapies. The paradigm shift of the pharma industry towards personalized medicine will additionally lend traction to nanotechnology-enabled drug delivery therapies that target the molecular cause of the disease. Poised to gain in the future are delivery systems that enable individualized pharmacotyping and patient specific delivery of drugs. The study estimates Nanotechnology in Drug Delivery to be a multi-million dollar market worldwide, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.

The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.

Developed for Drug Developers/Manufacturers, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.

For more details about how you can participate, please click here.

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website